RP-6306 + Chemotherapy for Ovarian and Uterine Cancer

(GyneRep Trial)

Overseen By Stephanie Lheureux, MD

Age: 18+

Sex: Female

Trial Phase: Phase 1

Sponsor: University Health Network, Toronto

Must be taking: Carboplatin, Paclitaxel

Must not be taking: Strong CYP3A inhibitors, inducers

Disqualifiers: Pregnancy, Uncontrolled infection, Cardiac diseases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 42

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new drug, RP-6306, combined with two chemotherapy drugs, carboplatin and paclitaxel, to determine its safety and effectiveness in treating ovarian or uterine cancer with a specific genetic change (TP53 mutation). The study aims to identify the optimal dose and schedule for the treatment, assessing its safety and any early signs of effectiveness. Women with advanced ovarian or uterine cancer with this genetic change and no other curative options may be suitable candidates for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

Do I need to stop my current medications to join the trial?

The trial requires that you stop taking chemotherapy or small molecule antineoplastic agents at least 21 days before starting the study treatment. Additionally, you should not be on strong CYP3A inhibitors or inducers within 14 days prior to the first dose. For other medications, the protocol does not specify, so it's best to discuss with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

In a previous study, researchers tested a new drug called RP-6306 to assess its safety for patients with advanced cancer and its effects on the cancer. They aimed to determine if patients could take RP-6306 without experiencing severe problems.

Carboplatin, a chemotherapy drug, often treats ovarian cancer. Research has shown that carboplatin is generally safe, even for older, more fragile patients. It helps treat ovarian and uterine cancer when combined with other drugs.

Paclitaxel is another chemotherapy drug used for ovarian cancer treatment. Studies have confirmed that paclitaxel is safe for most patients, with no serious allergic reactions reported in those with ovarian or uterine cancer.

Overall, while RP-6306 is newer and still under study, carboplatin and paclitaxel have a history of being fairly safe for treating cancers like ovarian and uterine. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatment for ovarian and uterine cancer?

Most treatments for ovarian and uterine cancer, like carboplatin and paclitaxel, work by damaging cancer cell DNA or preventing cell division. But RP-6306 works differently, targeting a specific protein that plays a role in DNA damage repair mechanisms, potentially making cancer cells more vulnerable to chemotherapy. Researchers are excited about RP-6306 because it could enhance the effectiveness of standard chemotherapy drugs, offering a promising new approach for patients with these types of cancer. This combination might improve outcomes by making cancer cells more sensitive to treatments they might otherwise resist.

What evidence suggests that this trial's treatments could be effective for ovarian and uterine cancer?

Studies have shown that using carboplatin and paclitaxel together effectively treats ovarian and uterine cancers. In patients with advanced or recurrent endometrial cancer, this combination has been linked to better survival rates. Paclitaxel alone has also demonstrated a strong ability to shrink tumors, making it a good option for ovarian cancer.

In this trial, participants will receive a combination of RP-6306 with carboplatin and paclitaxel. Early research on RP-6306 suggests it can enhance the effects of other cancer drugs. Lab studies have shown that it effectively slows cancer cell growth. Although information from human studies remains limited, combining RP-6306 with carboplatin and paclitaxel might increase treatment effectiveness. ^{2 3 6 7 8}

Who Is on the Research Team?

Stephanie Lheureux

Principal Investigator

The Princess Margaret Cancer Foundation

Are You a Good Fit for This Trial?

This trial is for women over 18 with advanced or recurrent ovarian and uterine cancer that's TP53 mutated, who can take oral meds, have good organ function, are not pregnant, and agree to use contraception. Excluded are those with recent major surgery, life-threatening conditions, uncontrolled infections like HIV/Hepatitis B/C, severe liver impairment or heart disease.

Inclusion Criteria

My ovarian or uterine cancer is advanced, cannot be cured with existing treatments.

I have tissue samples available for genetic testing.

My organs are functioning well enough for the study.

Exclusion Criteria

I haven't had chemotherapy or targeted cancer drugs within the last 3 weeks.

I don't have any health issues that could affect the study's results or my participation.

I am not allergic to RP-6306, carboplatin, or paclitaxel, or I can take them with steroids.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Determine the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RP2D) of RP-6306 in combination with carboplatin and paclitaxel

21-day cycles

Visits every 21 days

Dose Expansion

Further assess the safety and tolerability and determine the preliminary efficacy of RP-6306 in combination with carboplatin and paclitaxel

21-day cycles

Visits every 21 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Carboplatin
• Paclitaxel
• RP-6306

Trial Overview The study tests RP-6306 combined with carboplatin and paclitaxel in patients. It aims to find the safest dose (MTD) and see how well it works (efficacy). The first part sets the dose; the second part expands on safety data and preliminary effectiveness.

How Is the Trial Designed?

Group I: Part B - Dose Expansion Experimental Treatment 3 Interventions

RP6306, 40 mg orally at the best schedule determined in Part A. Carboplatin, AUC 5 intravenously, on Day 1 of every 21-day cycle. Paclitaxel, 175 mg/m2 intravenously, on Day 1 every 21-day cycle.

Group II: Part A - Dose Escalation Experimental Treatment 3 Interventions

RP6306, 40 mg orally, twice a day, continuously or on Days 1 to 3, for 1 or 2 weeks, every 21-day cycle. Carboplatin, AUC 5 intravenously, on Day 1 of every 21-day cycle. Paclitaxel, 175 mg/m2 intravenously, on Day 1 of every 21-day cycle.

Carboplatin is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Paraplatin for:

• Ovarian cancer
• Testicular cancer
• Lung cancer
• Head and neck cancer
• Brain cancer

Approved in European Union as Carboplatin for:

• Ovarian cancer
• Small cell lung cancer

Approved in Canada as Carboplatin for:

• Ovarian cancer
• Small cell lung cancer
• Testicular cancer

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials

1,555

Recruited

526,000+

Published Research Related to This Trial

In a study of 40 patients with ovarian, fallopian tube, or peritoneal cancers, the docetaxel/carboplatin regimen resulted in significantly higher rates of hematologic toxicity, with 80% of patients experiencing some form of it, including severe neutropenia in 45%.

Conversely, the paclitaxel/carboplatin group had a lower incidence of neutropenia and a higher occurrence of neuropathy, but both treatment regimens showed equivalent therapeutic efficacy, indicating that while side effects differ, the effectiveness in treating cancer remains similar.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Hsu, Y., Sood, AK., Sorosky, JI.[2019]

In a trial involving 59 women with advanced ovarian cancer, the combination of paclitaxel and carboplatin resulted in a high response rate of 72%, indicating effective treatment for this patient population.

Patients experienced significant improvements in quality of life during the outpatient treatment, with median survival times of 30.1 months for those with measurable disease, suggesting that this regimen is both effective and well-tolerated.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93). Schink, JC., Weller, E., Harris, LS., et al.[2015]

In a study of 22 high-risk ovarian cancer patients treated with adjuvant paclitaxel and carboplatin, the treatment was generally well tolerated, with manageable side effects and a high completion rate of therapy (77% without delays).

The treatment led to significant clinical outcomes, with 16 out of 19 patients with advanced disease achieving complete clinical remission after six cycles, indicating strong efficacy in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma. Coleman, RL., Bagnell, KG., Townley, PM.[2015]

In a study involving 247 patients with advanced ovarian cancer, both treatment regimens (standard carboplatin plus paclitaxel and alternating carboplatin/cisplatin plus paclitaxel) showed similar efficacy, with no significant differences in progression-free survival (PFS) or overall survival.

Both regimens were well tolerated, indicating that while the alternating regimen does not provide additional benefits, it is a safe option for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Aravantinos, G., Fountzilas, G., Kosmidis, P., et al.[2022]

The maximum tolerated doses (MTD) of ABI-007 in combination with carboplatin were determined to be 300 mg/m², 100 mg/m², and 125 mg/m² for three different treatment schedules, indicating a well-defined dosing strategy for future studies.

The combination therapy was well tolerated with a lower incidence of severe neutropenia compared to traditional solvent-based paclitaxel, showing promising activity against various solid tumors, including lung and breast cancers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Stinchcombe, TE., Socinski, MA., Walko, CM., et al.[2018]

Cytoreductive surgery followed by platinum-based chemotherapy, particularly with carboplatin, remains the standard treatment for advanced epithelial ovarian cancer, but most patients are not cured, highlighting the need for improved therapies.

Paclitaxel, a novel agent effective in platinum-resistant ovarian cancer, is being tested in combination with platinum compounds in clinical trials for previously untreated patients, aiming to enhance treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of ovarian cancer: current status. Ozols, RF.[2015]

In a study of 62 patients with ovarian, fallopian tube, or primary peritoneal cancer, BRCA mutations did not significantly increase the likelihood of hypersensitivity reactions (HSRs) to carboplatin, with 30.8% of BRCA-mutated patients experiencing reactions compared to 44.9% of BRCA wild-type patients.

However, BRCA mutations were significantly associated with a lower incidence of HSRs to paclitaxel, where only 7.7% of BRCA-mutated patients had reactions compared to 53.1% of BRCA wild-type patients, indicating a potential protective effect of BRCA mutations against paclitaxel-related hypersensitivity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations. Garcia, A., Frahm, C., Jeter, JM., et al.[2023]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7676887/

Carboplatin and Paclitaxel for Advanced Endometrial Cancer This was the first trial to show a survival advantage for combination chemotherapy in patients with measurable advanced or recurrent endometrial cancer. For ...

2. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/38264391/

Comparison of the Efficacy of Cisplatin/Paclitaxel Versus ... We concluded that the carboplatin/paclitaxel doublet endows a better quality of life (QOL) to patients along with significantly fewer gastrointestinal and ...

3. jamanetwork.com jamanetwork.com/journals/jamaoncology/fullarticle/2778657

Efficacy and Safety of First-line Single-Agent Carboplatin ... In this randomized clinical trial of 120 vulnerable older patients with ovarian cancer, single-agent carboplatin was less feasible and active than a ...

4. nejm.org nejm.org/doi/full/10.1056/NEJMoa1505067

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for ... In conclusion, our data suggest that weekly paclitaxel did not prolong progression-free survival, as compared with paclitaxel administered every ...

5. onlinelibrary.wiley.com onlinelibrary.wiley.com/doi/10.1155/2023/1951412

Efficacy and Safety of Paclitaxel and Carboplatin for ... Conclusion. Current evidence suggests that paclitaxel and carboplatin do not produce more satisfactory results with respect to overall survival ...

6. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/39231541/

A multicenter retrospective study to assess feasibility, ... Our data demonstrates that standard 3wCP is a well-tolerated, feasible first-line treatment for frail, elderly ovarian cancer patients.

7. ascopubs.org ascopubs.org/doi/10.1200/JCO.20.01076

Carboplatin and Paclitaxel for Advanced Endometrial Cancer This was the first trial to show a survival advantage for combination chemotherapy in patients with measurable advanced or recurrent endometrial ...

8. clinicaltrials.gov clinicaltrials.gov/study/NCT05963334

Study Details | NCT05963334 | Comparison of Weekly ... The aim of the current study is to compare weekly versus three-week collective of carboplatin/paclitaxel in advanced epithelial ovarian cancer.